SCHEMBL3362967

SCHEMBL3362967

COC(=O)c1cc(S(N)(=O)=O)ccc1F

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 13/20 0.58
ALDH1A1 P00352 1/20 0.56
HPGD P15428 1/20 0.56
TSHR P16473 1/20 0.56
HSD17B10 Q99714 1/20 0.56
YAP1 P46937 1/20 0.54
CA1 P00915 10/20 0.51
CA9 Q16790 8/20 0.51
CA12 O43570 5/20 0.51
CA14 Q9ULX7 3/20 0.51
GAA P10253 2/20 0.49
CA5A P35218 2/20 0.49
PTGS1 P23219 2/20 0.47
PTGS2 P35354 2/20 0.47
CA4 P22748 1/20 0.46
CA6 P23280 1/20 0.46
CA7 P43166 1/20 0.46
CA5B Q9Y2D0 1/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22867087 0.87 CA2 (0.55) CA2YAP1CA1CA9CA12
SCHEMBL2642360 0.85 TSHR (0.58) CA2ALDH1A1HPGDTSHRHSD17B10
SCHEMBL17478992 0.84 ALDH1A1 (0.56) CA2ALDH1A1HPGDTSHRHSD17B10
SCHEMBL4419601 0.83 PTGS2 (0.63) CA2TSHRYAP1CA1CA9
SCHEMBL20766290 0.83 TSHR (0.55) CA2ALDH1A1HPGDTSHRHSD17B10
SCHEMBL14683630 0.83 TSHR (0.55) CA2ALDH1A1HPGDTSHRHSD17B10
SCHEMBL25235102 0.82 CA2 (0.59) CA2ALDH1A1HPGDTSHRHSD17B10
SCHEMBL16790372 0.82 CA2 (0.59) CA2YAP1CA1CA9CA12
SCHEMBL7145771 0.81 CA2 (0.55) CA2CA1CA9CA12CA14
SCHEMBL6151646 0.81 CA2 (0.56) CA2CA1CA9CA12CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030879-B2 Sulfonyl acetamides as NLRP3 inhibitors INFLAZOME LIMITED (IE) 2024-07-09 US disclosed
US-20210002274-A1 NOVEL COMPOUNDS INFLAZOME LIMITED (IE) 2021-01-07 US disclosed
US-20210002274-A1 NOVEL COMPOUNDS INFLAZOME LIMITED (IE) 2021-01-07 US disclosed
EP-3759090-A1 NOVEL COMPOUNDS Inflazome Limited (IE) 2021-01-06 EP disclosed
CN-110511173-A A kind of indolyl piperazine benzamide compound and its application UNIV FUDAN 2019-11-29 CN disclosed
US-20100009970-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES COMBINATORX (SINGAPORE) PTE. LTD. (SG) 2010-01-14 US disclosed
US-20100009970-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES COMBINATORX (SINGAPORE) PTE. LTD. (SG) 2010-01-14 US disclosed
US-20100009970-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES COMBINATORX (SINGAPORE) PTE. LTD. (SG) 2010-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009970-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES HTR1A, HTR3B, HTR3A CA2 4884/4885ALDH1A1 2240/4885HPGD 3754/4885
US-12030879-B2 Sulfonyl acetamides as NLRP3 inhibitors NLRP3, NOD1, NLRP1 CA2 624/4885ALDH1A1 1078/4885HPGD 1670/4885
US-20210002274-A1 NOVEL COMPOUNDS NLRP3, NOD1, NLRP1 CA2 1129/4885ALDH1A1 1160/4885HPGD 764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.